KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Assets (2016 - 2025)

NovoCure (NVCR) has disclosed Non-Current Assets for 12 consecutive years, with $157.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 17.43% to $157.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $157.6 million through Dec 2025, up 17.43% year-over-year, with the annual reading at $157.6 million for FY2025, 17.43% up from the prior year.
  • Non-Current Assets hit $157.6 million in Q4 2025 for NovoCure, down from $161.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $162.6 million in Q2 2025 to a low of $51.4 million in Q3 2021.
  • Historically, Non-Current Assets has averaged $102.0 million across 5 years, with a median of $95.9 million in 2023.
  • Biggest five-year swings in Non-Current Assets: rose 8.16% in 2021 and later skyrocketed 39.64% in 2022.
  • Year by year, Non-Current Assets stood at $66.0 million in 2021, then increased by 21.45% to $80.1 million in 2022, then skyrocketed by 39.44% to $111.7 million in 2023, then grew by 20.13% to $134.2 million in 2024, then rose by 17.43% to $157.6 million in 2025.
  • Business Quant data shows Non-Current Assets for NVCR at $157.6 million in Q4 2025, $161.3 million in Q3 2025, and $162.6 million in Q2 2025.